Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue | $41.7M | $54.1M | $95.0M | $139.8M | $169.9M |
| Cost of revenue | $13.0M | $17.5M | $36.8M | $45.3M | $71.0M |
| Gross profit | $28.7M | $36.6M | $58.2M | $94.5M | $98.9M |
| Gross margin | 68.8% | 67.7% | 61.3% | 67.6% | 58.2% |
| R&D | $4.8M | $9.6M | $22.1M | $26.3M | $30.6M |
| Operating income | −$10.7M | −$6.1M | −$44.7M | −$30.6M | −$49.9M |
| EBITDA | −$2.8M | $6.5M | −$30.4M | $4.1M | −$30.9M |
| Net income | −$17.9M | −$6.8M | −$38.3M | −$12.9M | −$31.7M |
| Net margin | -42.9% | -12.5% | -40.4% | -9.2% | -18.6% |
| EPS (diluted) | -0.15 | -0.06 | -0.39 | -0.11 | -0.26 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $282M | $0.05 | $0.05–$0.05 | 1 |
| 2027 | $341M | $0.23 | $0.23–$0.23 | 1 |
| 2028 | $406M | $0.43 | $0.43–$0.43 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds OLK.
No tracked institution reports a position in OLK as of their last filing.
No one on the platform has traded OLK yet.
| $2.9B |
| — |
| MORFMorphic Holding, Inc. | $56.99 | +0.04% | $2.9B | — |
| ONEM1Life Healthcare, Inc. | $16.47 | +0.00% | $3.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 21.5× sales vs its 15.1× historical median P/S.
Fair value ≈ $18.33 · price $26.08 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
@Lexy911 also noteworthy that PPD (the clinical trial research arm running our ARDS trial) is a wholly owned subsidiary of $TMO Thermo Fischer Our head of investor relations Jan Medina was most recently running investor relations for $OLK. He left $OLK to join Inflarx after he successfully participated in negotiations of a buyout of Olink by Thermo over 150% premium ($10 to $26). A very well connected individual with noted experience as analyst, biotech expert, M&A, and capital markets. Good addition to inflarx.
View on StockTwits ↗@Nelsin 525 is the low. My target is 615 by 08/30. I think it's setting up for a monster August. Newly declared dividend and $OLK acquisition haven't been fixed into the price yet. Crossing my fingers they also announce a buyback
View on StockTwits ↗$UNH, $TMO & $ELF are earning giants. Pay attention to $ELF Monday morning as it slides back to 202-205 and hopefully 198-200. Always a great idea to buy calls in that range. Follow it's patterns closely and you'll see why it's the gift that keeps on giving. $UNH earnings Tuesday morning. Despite the recent pop, I still see another 8-10% upside. $TMO is my monster for the summer. Biggest medical technology company in the world with tremendous upside for years to come. Newly declared cash dividend and $OLK acquisition will send it to the moon with a +12-15%. These are my monsters this month. I know we all love the mag 7 but these companies will provide a more bang for your buck in my opinion. Research and trade carefully. Predictions for 08/30 $ELF 240-250 $UNH 580-600 $TMO 590-625
View on StockTwits ↗$TSLA while you're all fighting over this disaster, I'll drop you an earnings giant. $TMO is going to explode. It's my big bull of the month. 12%-15% upside. Declared a quarterly cash dividend after close today and acquired $OLK two days ago. Monster of a stock. Check it out and trade carefully.
View on StockTwits ↗$OLK trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $26.02 Vol: 1.89M.
View on StockTwits ↗It's done, $TMO has been cleared to acquire Swedish biotech company $OLK. That's a +6.4% return / +16.2% annualized return for me and win 4/4 on merger arb deals. Merger arbitrage is a great strategy if you pick reasonable deals and be patient 👌
View on StockTwits ↗$OLK $TMO - Tender Offer Expires @ 5pm MergerBrief.com
View on StockTwits ↗$OLK Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher https://www.stocktitan.net/news/OLK/olink-announces-receipt-of-cma-clearance-for-proposed-acquisition-by-pq8a3vk6lms4.html
View on StockTwits ↗$OLK German regulators clear the acquisition by $TMO. UK CMA decision still pending after phase I investigation.
View on StockTwits ↗Signal alert: $OLK - Overbought Trend Short (Overvalued) https://stockinvest.us/l/SEi58VNbg9
View on StockTwits ↗$OLK Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis https://www.stocktitan.net/news/OLK/researchers-use-olink-r-explore-to-identify-circulating-proteins-xlyittslgge1.html
View on StockTwits ↗$OLK reported a loss of $0.13, consensus was ($0.12) via @eWhispers #epsmiss http://eps.sh/d/olk
View on StockTwits ↗$OLK Olink reports Q1 EPS (13c), consensus (15c) Reports Q1 revenue $28.8M, consensus $30.22M.
View on StockTwits ↗$OLK Olink reports first quarter 2024 financial results https://www.stocktitan.net/news/OLK/olink-reports-first-quarter-2024-financial-8zzl5v9aaxi4.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.